cPass SARS-CoV-2 Neutralization Antibody Detection Kit is an in vitro diagnostic test kit manufactured by GenScript for the detection of SARS-CoV-2 neutralization antibody.
This document provides detailed instructions for using the cPass SARS-CoV-2 Neutralization Antibody Detection Kit, a blocking ELISA designed to detect total neutralizing antibodies to SARS-CoV-2 in human serum and plasma. The kit is intended for use in certified laboratories under FDA Emergency Use Authorization and is not for diagnosing acute infection. Results indicate the presence of neutralizing antibodies but do not confirm immunity or protection from infection.
The kit includes pre-coated plates, controls, and reagents for performing the assay. It uses purified hACE2 protein and HRP-conjugated RBD to detect antibodies that block the RBD-hACE2 interaction. The test is semi-quantitative and requires specific handling and storage conditions to ensure accurate results.
The cPass SARS-CoV-2 Neutralization Antibody Detection Kit is intended for the qualitative and semi-quantitative direct detection of total neutralizing antibodies to SARS-CoV-2 in human serum and dipotassium EDTA plasma.
No, the kit should not be used to diagnose or exclude acute SARS-CoV-2 infection.
The kit is a blocking ELISA that detects functional immunoglobulins neutralizing the interaction between RBD and hACE2.
The unopened kit is stable at 2°C to 8°C until expiration date and the opened kit is stable for up to 1 month from the date of opening at 2°C to 8°C.